Related Experiment Videos
Plasma thromboxane B2 in haemodialysed patients
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1985
Summary
Patients with kidney failure show higher thromboxane B2 (TXB2) levels. Hemodialysis further increased TXB2, suggesting a role in atherosclerosis for these patients.
Area of Science:
- Nephrology
- Cardiovascular Research
- Biochemistry
Background:
- Uremic patients undergoing chronic hemodialysis often develop accelerated atherosclerosis.
- Thromboxane B2 (TXB2) is a marker of thromboxane production, implicated in cardiovascular disease.
Purpose of the Study:
- To investigate plasma TXB2 concentrations in patients with terminal renal failure.
- To assess the effect of hemodialysis on TXB2 levels in these patients.
Main Methods:
- Plasma TXB2 levels were measured in 7 patients with end-stage renal disease.
- Measurements were taken before and after hemodialysis sessions.
- A control group was used for comparison.
Main Results:
- Plasma TXB2 concentrations were significantly higher in patients with renal failure compared to controls (p < 0.05).
- Hemodialysis led to a further statistically significant increase in TXB2 levels.
Conclusions:
- Elevated TXB2 production is present in patients with terminal renal failure.
- Hemodialysis exacerbates TXB2 levels, potentially contributing to the pathogenesis of atherosclerosis in uremic patients.